LA JOLLA—Tickets are now available for the 29th annual Symphonie im Salk, an evening where music, science, and philanthropy converge for a spectacular celebration. Set against the backdrop of the Salk Institute’s iconic architecture, this exclusive event will take place on Saturday, August 16, 2025, and feature the San Diego Symphony performing with Emmy and Tony Award-winning performer Kristin Chenoweth.
Guests will experience the elegance of the evening with a champagne reception, gourmet dinner, and immersive musical performances, all while contributing to the Salk Institute’s mission to better understand and address some of the world’s most pressing challenges.
This year’s event will feature a special focus on Salk’s Year of Alzheimer’s Disease Research. Guests will learn how Salk scientists are rewriting the narrative on Alzheimer’s, a devastating disease that continues to take a heartbreaking toll on families despite decades of investment. Cross-disciplinary Salk teams are now exploring a largely overlooked driver of the disease—chronic inflammation—rather than focusing solely on traditional hallmarks. By investigating this underlying factor across all brain cell types, not just neurons, they are uncovering new avenues for early detection and treatment.
“Symphony at Salk is more than just a concert—it is an opportunity to celebrate the profound intersection of art and science,” says Amy Jacobs, member of Salk’s Board of Trustees and chair of the Symphony at Salk committee. “As Salk scientists continue to push the boundaries of knowledge in Alzheimer’s and other critical areas of research, events like this help bring those breakthroughs to life.”
Tickets, sponsorships, and advertising opportunities can be purchased at symphony.salk.edu.
Büro für Kommunikation
Telefon: (858) 453-4100
press@salk.edu
Das Salk Institute ist ein unabhängiges, gemeinnütziges Forschungsinstitut, das 1960 von Jonas Salk, dem Entwickler des ersten sicheren und wirksamen Polio-Impfstoffs, gegründet wurde. Die Aufgabe des Instituts besteht darin, grundlegende, kooperative und risikofreudige Forschung voranzutreiben, die sich mit den dringendsten Herausforderungen der Gesellschaft befasst, darunter Krebs, Alzheimer und die Gefährdung der Landwirtschaft. Diese Grundlagenforschung bildet die Basis für alle translationalen Bemühungen und führt zu Erkenntnissen, die neue Medikamente und Innovationen weltweit ermöglichen.
